Development and verification of the PAM50-based Prosigna breast cancer gene signature assay

BACKGROUND: The four intrinsic subtypes of breast cancer, defined by differential expression of 50 genes (PAM50), have been shown to be predictive of risk of recurrence and benefit of hormonal therapy and chemotherapy. Here we describe the development of Prosigna™, a PAM50-based subtype classifier a...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMC Med Genomics
Autori principali: Wallden, Brett, Storhoff, James, Nielsen, Torsten, Dowidar, Naeem, Schaper, Carl, Ferree, Sean, Liu, Shuzhen, Leung, Samuel, Geiss, Gary, Snider, Jacqueline, Vickery, Tammi, Davies, Sherri R., Mardis, Elaine R., Gnant, Michael, Sestak, Ivana, Ellis, Matthew J., Perou, Charles M., Bernard, Philip S., Parker, Joel S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2015
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4546262/
https://ncbi.nlm.nih.gov/pubmed/26297356
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12920-015-0129-6
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi